^
    Back
    Association details:
    Biomarker:TNFRSF17 underexpression
    Cancer:Multiple Myeloma
    Drug:CTX-8573 (NK cell stimulant, BCMA inhibitor, CD16A agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

    Published date:
    11/06/2019
    Excerpt:
    In-vivo, CTX-8573 demonstrates anti-tumor efficacy in multiple humanized mouse models including killing of low BCMA expressing cell lines. 
    DOI:
    https://doi.org/10.1182/blood-2019-128749